No current peripheral neuropathy > grade 2 at time of randomization
Peripheral neuropathy Grade ? 2
Peripheral neuropathy of any etiology that exceeds grade 1
Patients must not have baseline peripheral neuropathy that exceeds grade 1
=< grade 2 peripheral neuropathy; patients with grade 1 peripheral neuropathy with pain will be excluded
=< grade 2 peripheral neuropathy
Peripheral neuropathy >= 2
Grade >= 2 peripheral neuropathy
Patients with a baseline peripheral neuropathy >= grade 2 will not be eligible
Patients with preexisting grade II peripheral neuropathy
Peripheral neuropathy ? Grade 2.
Grade >= 2 peripheral neuropathy at the present time
Peripheral neuropathy of Grade 2 within 3 weeks prior to the first study therapy
Peripheral neuropathy ?grade 3.
Peripheral neuropathy >= grade 2 at screening
Peripheral neuropathy > Grade 2 despite supportive therapy.
Participants with >= grade 2 peripheral neuropathy
Baseline peripheral neuropathy of severity > grade 1
Presence of >= grade 2 peripheral neuropathy
Peripheral neuropathy >= grade 2
Presence of peripheral neuropathy > grade 1
Peripheral neuropathy =< grade 1 at the time of registration
Presence of > grade 1 peripheral neuropathy
Peripheral neuropathy >Grade 2
Patients must not have peripheral neuropathy ? grade 2
Grade >= 2 peripheral neuropathy
Peripheral neuropathy > grade 1
Peripheral neuropathy > CTCAE grade 1
Clinically significant (>= grade 2) peripheral neuropathy at the time of study entry
Peripheral neuropathy grade > 1
Has greater than Grade 1 peripheral sensory neuropathy or > Grade 1 peripheral motor neuropathy graded according to the Modified (\Balis\) Pediatric Scale of Peripheral Neuropathies.
CTCAE grade >= 2 peripheral neuropathy is NOT permitted
Effects of any other prior therapies not reverted to ? Grade 1 (or ? Grade 2 for alopecia and peripheral neuropathy).
Active >= grade 3 peripheral neuropathy
Peripheral neuropathy > grade 1
Patients with > grade 1 peripheral neuropathy
Peripheral neuropathy grade 1 or less.
No peripheral neuropathy
Baseline grade II peripheral neuropathy
Current peripheral neuropathy >= grade 2
Peripheral neuropathy >= grade 2 at screening
Patients with a peripheral neuropathy > grade 1
Peripheral neuropathy >= grade 2
Baseline grade II peripheral neuropathy
Patients with a peripheral neuropathy > grade 1
ENTRECTINIB EXCLUSION CRITERIA: Peripheral neuropathy >= grade 2
Grade >= 2 peripheral neuropathy at baseline (within 21 days prior to cycle 1 day 1)
Patients with peripheral neuropathy of > grade 1
No peripheral neuropathy >= grade 2 at baseline
Peripheral neuropathy, if present, should be =< grade 1
Peripheral neuropathy > grade 1 if due to brentuximab vedotin or any peripheral neuropathy > grade 2
Peripheral neuropathy grade 0-2
Patients with preexisting peripheral neuropathy >= grade 2 are ineligible
Patients with grade >= 2 peripheral neuropathy
For the bortezomib arm of the study, patients with grade >= 2 peripheral neuropathy
Peripheral neuropathy > grade 1
Peripheral neuropathy >= grade 1
Has > Grade 1 peripheral sensory neuropathy or > Grade 1 peripheral motor neuropathy graded according to the Modified (\Balis\) Pediatric Scale of Peripheral Neuropathies
CTCAE v4 Grade ?2 peripheral neuropathy
Grade >= 2 peripheral neuropathy
Preexisting peripheral neuropathy is not allowed from any cause
Grade >= 2 peripheral neuropathy
>= grade 2 peripheral neuropathy
Peripheral neuropathy >= grade 2 despite supportive therapy
Patients with existing grade 3 or 4 peripheral neuropathy
Peripheral neuropathy >= grade 2 at baseline OR peripheral neuropathy >= grade I with neuropathic pain
Patients with grade 3/4 peripheral neuropathy
Patients who have baseline peripheral neuropathy >= grade 2 are not eligible
Grade > 2 peripheral neuropathy at baseline (within 14 days prior to cycle 1 day 1)
Subject has >= grade 2 peripheral neuropathy
Peripheral neuropathy >= grade 2
Patients with > grade 1 peripheral sensory neuropathy or > grade 1 peripheral motor neuropathy graded according to the Modified (“Balis”) Pediatric Scale of Peripheral Neuropathies are not eligible
Peripheral neuropathy >= grade 2
Peripheral neuropathy >= grade 2
Peripheral neuropathy =< grade 1
>= grade 2 peripheral neuropathy
>= grade 2 peripheral neuropathy within 14 days before beginning maintenance therapy
Patients with >= grade 2 peripheral neuropathy
Patients must not have peripheral neuropathy >= grade 2
Patients with peripheral neuropathy > grade 2 regardless of etiology
Has peripheral neuropathy ? Grade 2.
Peripheral neuropathy =< grade 1
Has peripheral neuropathy ? Grade 2
Subjects with baseline peripheral neuropathy that exceeds grade 1
Significant symptoms (grade >= 2) peripheral neuropathy
Peripheral neuropathy ? Grade 3 or ? Grade 2 with pain within 2 weeks prior to first dose
Peripheral neuropathy ? Grade 2
Peripheral neuropathy ? Grade 2.
Has peripheral neuropathy ? Grade 2
Current Grade >1 peripheral neuropathy
Grade ? 2 peripheral neuropathy
Peripheral neuropathy < grade 2
Grade >= 2 peripheral neuropathy
Current Grade >1 peripheral neuropathy from any cause
Patients must not have peripheral neuropathy > grade 2
Peripheral neuropathy exclusions
? Grade 2 peripheral neuropathy
Baseline peripheral neuropathy/paresthesia grade >= 1
Serious peripheral neuropathy.
Peripheral neuropathy ? Grade 2.
Previous diagnosis of diabetic neuropathy or peripheral neuropathy from any cause
Participants who have more than grade 1 peripheral neuropathy
Peripheral neuropathy >= grade 2
Peripheral neuropathy < grade 2
Clinically significant peripheral neuropathy
Has baseline peripheral neuropathy/paresthesia grade ? 1.
Evidence of peripheral neuropathy of Grade >2.
Subject has peripheral neuropathy ? grade 2.
Peripheral neuropathy >= grade 1
Grade 3 or above peripheral neuropathy
Peripheral neuropathy: must be =< grade 1
Grade > 2 peripheral neuropathy at baseline
Grade >= 2 peripheral neuropathy within 14 days prior to cycle 1 day 1
Patients with existing peripheral neuropathy grade > 2
Peripheral neuropathy =< grade 1 at the time of registration
Grade >= 2 peripheral neuropathy within 14 days prior to initiation of therapy
Subject has peripheral neuropathy >= grade 2.
Presence of peripheral neuropathy ? CTCAE Grade 2
Peripheral neuropathy ? Grade 2 despite supportive therapy
Has baseline peripheral neuropathy/paresthesia
COHORT II: Patients must not have >= grade 2 peripheral neuropathy
Peripheral neuropathy > Grade 2.
Peripheral neuropathy >= grade 2 at baseline OR peripheral neuropathy >= grade I with neuropathic pain
Peripheral neuropathy: must be =< grade 1
Grade 2 or more peripheral neuropathy
Peripheral neuropathy of grade >=3. Patients with painful grade 2 neuropathy are also excluded
Peripheral neuropathy ? Grade 2
Peripheral neuropathy >= grade 3
No ? grade 2 peripheral neuropathy.
CTCAE version 4.03 > grade 3 peripheral neuropathy
Peripheral neuropathy =< grade 1
Peripheral neuropathy >= grade (Gr) II
Peripheral neuropathy =< grade 1
Peripheral neuropathy >/= Grade 2 (NCI-CTC Version 3.0)
Grade 3 peripheral neuropathy
Patients with peripheral neuropathy of grade >= 3; patients with painful grade 2 neuropathy are also excluded
Peripheral neuropathy
Peripheral neuropathy > grade 2
> grade 2 peripheral neuropathy at baseline
Presence of ? Grade 2 peripheral neuropathy
Peripheral neuropathy ? Grade 3.
Presence of clinically significant non-hematological toxicity of prior chemotherapy that has not resolved to ? Grade 1 as determined by CTCAE v 4.0, with the exception of alopecia and peripheral neuropathy. Note: Peripheral neuropathy > Grade 2 plus pain, or Grade 3 or Grade 4 are excluded.
Presence of > Grade 1 peripheral neuropathy
Peripheral neuropathy CTCAE Grade ?2
Peripheral neuropathy ? Grade 2
Patients with peripheral neuropathy > 2
Baseline peripheral neuropathy ? grade 2.
Peripheral neuropathy ? grade 2.
Grade >= 2 peripheral neuropathy
Patients with grade >= 2 peripheral neuropathy will not be permitted on study
Patients with preexisting peripheral neuropathy grade >= 2 will not be eligible
Evidence of peripheral neuropathy of Grade > 2
Subjects with > grade 1 peripheral neuropathy
Patients with > grade 2 neuropathy according to the Modified (“Balis”) Pediatric Scale of Peripheral Neuropathies will be excluded except in cases in which neuropathy is secondary to prior surgery
Peripheral neuropathy Grade >/=2
Subjects with preexisting Grade 3 or 4 neuropathy. Any peripheral neuropathy must recover to Grade less than or equal to 2 before enrollment
Presence of peripheral neuropathy
Subjects with Grade >2 peripheral neuropathy
Peripheral neuropathy at study entry
Peripheral neuropathy CTCAE v4.03 Grade ? 3
Patients with peripheral neuropathy >= grade 2
Peripheral neuropathy ? CTCAE Grade 2 at baseline.
Patients who have grade >= 2 peripheral neuropathy
Preexisting grade >= 2 peripheral neuropathy
Patients with peripheral neuropathy >= grade 2 are not permitted unless discussed with the principal investigator and only in unique circumstances (i.e. unilateral neuropathy due to trauma)
Ongoing Grade 3 or Grade 4 peripheral neuropathy, or Grade 2 peripheral neuropathy with pain despite appropriate interventions, within 28 days prior to first dose of study treatment.
No grade >= 2 peripheral neuropathy
Grade >=2 peripheral neuropathy
Part 2 only: Patients with >= grade 2 peripheral neuropathy.
Peripheral neuropathy ?Grade 2.
>= grade 2 peripheral neuropathy
Peripheral neuropathy
Patients with a >= grade 2 peripheral neuropathy
Current Grade >1 peripheral neuropathy
History of peripheral neuropathy; (note: this does not apply to Cohort 3)
Grade >=2 peripheral neuropathy
Patients with peripheral neuropathy >= grade 2
Grade ?2 peripheral neuropathy at baseline (within 14 days prior to cycle 1 day 1).
Peripheral neuropathy >= grade 2
Patient has > Grade 2 painful neuropathy or peripheral neuropathy
Peripheral neuropathy ? Grade 2
Patients with peripheral neuropathy > grade 1 will be excluded from study participation
History of peripheral neuropathy of ?grade 2
Patients with symptomatic peripheral neuropathy> Grade 1.
Peripheral neuropathy > grade 1 (NCI-CTC).
Peripheral neuropathy of > grade 2 severity.
Peripheral neuropathy ? CTCAE grade 2
Peripheral neuropathy with grade =< 1
Clinically significant (>= grade 2) peripheral neuropathy at the time of study entry
Peripheral neuropathy >= grade 1
Grade >= 2 peripheral neuropathy
Patients must not have a history of peripheral neuropathy (regardless of cause)
Any peripheral neuropathy >= grade 3
Patients with known, previously diagnosed peripheral neuropathy from causes other than chemotherapy
Grade III or IV upper extremity peripheral neuropathy
Self-report of >= 4 on the Peripheral Neuropathy Question
Patients with known, previously diagnosed peripheral neuropathy from causes other than chemotherapy.
History of peripheral neuropathy prior to receiving neurotoxic chemotherapy
Pain or symptoms of peripheral neuropathy of > 3 month's duration attributed to chemotherapy-induced peripheral neuropathy
Previous diagnosis of diabetic neuropathy or peripheral neuropathy from any cause
No >= grade 2 peripheral neuropathy
Peripheral neuropathy ? grade 2
